Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

testing; the therapeutic and commercial value of XL184 and our other compounds; our ability to initiate clinical trials for XL184 at the referenced times; and our ability to enter into new collaborations, continue existing collaborations and receive milestones and royalties under our collaborative agreements. These and other risk factors are discussed under "Risk Factors" and elsewhere in our quarterly report on Form 10-Q for the quarter ended March 28, 2008, and other filings with the Securities and Exchange Commission. We expressly disclaim any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... YORK and SANTA CLARA, Calif. ... Corp. (NASDAQ: WBMD ), the leading source ... new WebMD/Medscape survey that provide novel insights ... in aiding diagnosis and care.  Dr. Eric Topol ... and digital medicine, who serves as both Editor-in-Chief of ...
(Date:9/22/2014)... researchers at the USC Viterbi School of Engineering, ... microfluidic system quickly and cheaply by simply snapping ... systems are used in many fields including engineering, ... of fluids for use in applications such as ... testing, and synthetic chemistry. Traditionally, microfluidic devices are ...
(Date:9/22/2014)... cells (CTCs) in a mouse model of pancreatic cancer ... of CTCs, including significant differences from the primary tumor ... In their study reported in the Sept. 25 ... Massachusetts General Hospital (MGH) Cancer Center identified several different ... may prove to be targets for improved treatment of ...
(Date:9/22/2014)... of Minnesota electrical engineering researchers have developed a ... demonstrates mechanical transportation of light. The discovery could ... efficient optical devices for computation and communication. , ... and computer engineering assistant professor Mo Li and ... online and will appear in the October issue ...
Breaking Biology Technology:WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Engineers show light can play seesaw at the nanoscale 2
... and PHILADELPHIA, July 4 ,Shire Limited (LSE:SHP, NASDAQ: SHPGY), ... earnings on,Thursday 31 July 2008, Results press ... BST / 07:00 EDT Investor meeting and conference ... Investor & Analyst meeting and conference call:, Angus ...
... Research Group has,released results from aboratory testing ... at Oregon State University which,demonstrated the Eniva ... for human cells. This third party testing ... effort to further identify,mechanisms by which the ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today announced that ... its cash burn rate. As previously,announced, the Company ... acquisitions and mergers. In conjunction with this,process, the ... its VP,series of drugs, and has determined that ...
Cached Biology Technology:Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2Vasogen Provides Corporate Update 2
(Date:9/21/2014)... new strains of bacteria have emerged that resist even ... drug-resistant forms of tuberculosis and staphylococcus, infect more than ... Despite the urgent need for new treatments, scientists have ... past decade. , MIT engineers have now turned a ... system that can disable any target gene, they have ...
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... University of Oklahoma biology professor will study the unique ... that could eventually benefit people,s health. The OU ... the energy required to produce the signals used to ... electric signals at a rate of 500-600 discharges a ... for the electric fish are extreme, but necessary for ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... Hidenori Ichijo and Hideki Nishitoh (The University of Tokyo) ... genetics of ALS. Amyotrophic lateral sclerosis (ALS), also ... fatal neurological disease involving the degeneration and death of ... the most common neuromuscular diseases worldwide, affecting as roughly ...
... sturgeons, more caviar will be exported from Caspian Sea ... of unacceptably permissive new trade quotas announced Thursday by ... Most sturgeon species are endangered and some, like beluga ... damage this ancient fish,s chance of recovery and survival, ...
... New research* shows that while engineered nanomaterials can ... food chain from single celled organisms to higher ... and there was no evidence of the nanomaterials ... results observed by researchers from the National Institute ...
Cached Biology News:New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 2New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 4Research measures movement of nanomaterials in simple model food chain 2
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
Weinreb Linker...
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Biology Products: